Recro Pharma (REPH) Expected to Announce Quarterly Sales of $17.32 Million

Brokerages expect Recro Pharma (NASDAQ:REPH) to post $17.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $17.00 million and the highest estimate coming in at $17.64 million. Recro Pharma reported sales of $18.74 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 7.6%. The business is scheduled to announce its next quarterly earnings report on Thursday, May 10th.

According to Zacks, analysts expect that Recro Pharma will report full year sales of $74.30 million for the current year, with estimates ranging from $72.00 million to $78.00 million. For the next year, analysts anticipate that the business will post sales of $113.57 million per share, with estimates ranging from $102.50 million to $122.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Recro Pharma.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.22. The firm had revenue of $19.04 million during the quarter, compared to analysts’ expectations of $12.88 million. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%.

A number of equities analysts recently weighed in on REPH shares. UBS started coverage on shares of Recro Pharma in a research report on Tuesday, February 13th. They set an “outperform” rating for the company. Oppenheimer set a $19.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Wednesday, February 28th. CIBC started coverage on shares of Recro Pharma in a research report on Wednesday, February 14th. They set an “outperform” rating and a $19.00 price objective for the company. Zacks Investment Research raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 21st. Finally, ValuEngine upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Recro Pharma presently has an average rating of “Buy” and an average price target of $14.21.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 21.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Recro Pharma by 1.4% during the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after buying an additional 13,799 shares in the last quarter. Lyon Street Capital LLC acquired a new stake in shares of Recro Pharma in the 4th quarter valued at $3,362,000. Cadence Capital Management LLC raised its holdings in shares of Recro Pharma by 7.8% in the 4th quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 13,078 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Recro Pharma by 23.4% in the 4th quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after purchasing an additional 23,100 shares in the last quarter. Finally, JT Stratford LLC raised its holdings in shares of Recro Pharma by 7.8% in the 4th quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 8,120 shares in the last quarter. Institutional investors own 57.23% of the company’s stock.

Shares of NASDAQ:REPH traded down $0.27 during mid-day trading on Monday, reaching $11.19. 175,359 shares of the company were exchanged, compared to its average volume of 203,143. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.55 and a current ratio of 1.75. The stock has a market capitalization of $226.18, a P/E ratio of -5.63 and a beta of -0.75. Recro Pharma has a 1 year low of $5.81 and a 1 year high of $12.42.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply